文献速递慢性肾脏病肾小球疾病

巴多索隆甲基对糖尿病肾病GFR影响的随机临床试验(TSUBAKI研究)

Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study).
PubMed 文献 · Kidney Int Rep · 2020-04-14

TSUBAKI是一项2期随机双盲安慰剂对照研究,纳入2型糖尿病合并3-4期CKD患者,评估无心力衰竭风险因素者使用巴多索隆甲基是否可减轻液体超负荷风险,以及eGFR变化是否反映GFR真实升高。结果显示,巴多索隆甲基组菊粉清除率测得的GFR较基线显著升高,组间差异为6.64 ml/min/1.73 m²(P=0.008),但不良事件和停药率较高。

要点

  • 巴多索隆甲基使测得的GFR显著升高,组间差异6.64 ml/min/1.73 m²(P=0.008)。
  • 巴多索隆甲基组白蛋白/肌酐比值升高,外周水肿多为轻度和自限性。
  • 巴多索隆甲基组停药率高于安慰剂组,需进一步评估临床获益与安全性。

核心结论

  • 巴多索隆甲基显著升高了菊粉清除率测得的GFR,但其临床获益及在特定CKD患者中的安全性仍需进一步研究。

研究设计与样本

  • 2期随机、多中心、双盲、安慰剂对照研究,纳入2型糖尿病合并3-4期CKD患者。
  • G3队列按1:1随机至巴多索隆甲基(n=41)或安慰剂(n=41);G4队列按2:1随机至巴多索隆甲基(n=24)或安慰剂(n=14)。
  • 口服每日一次,采用剂量滴定方案,疗程16周;主要疗效终点为G3队列第16周菊粉清除率测得的GFR较基线变化。

主要发现

  • G3队列共40例患者纳入预设主要疗效分析。
  • 巴多索隆甲基组GFR平均变化为5.95(95%CI 2.29至9.60)ml/min/1.73 m²,安慰剂组为-0.69(95%CI -3.83至2.45)ml/min/1.73 m²。
  • 组间差异为6.64 ml/min/1.73 m²(P=0.008)。
  • 巴多索隆甲基组较安慰剂组白蛋白/肌酐比值升高。
  • 最常见不良事件(任一组≥15%)包括病毒性上呼吸道感染、丙氨酸氨基转移酶升高、天冬氨酸氨基转移酶升高、γ-谷氨酰转移酶升高和便秘;外周水肿在巴多索隆甲基组报告4例、安慰剂组1例,均为轻度且自限性;无患者死亡或发生心力衰竭。

临床怎么用

  • 对于无心力衰竭风险因素的2型糖尿病合并3-4期CKD患者,巴多索隆甲基可显著升高测得的GFR,但需监测白蛋白/肌酐比值、肝酶及液体超负荷相关不良事件。

局限性

  • 本研究为2期探索性研究,样本量较小,主要疗效分析仅纳入40例患者。
  • 研究期限为16周,长期肾脏获益和安全性尚未确定。
  • 研究排除了具有心力衰竭风险因素的患者,结果不能外推至该人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Bardoxolone methyl significantly increases estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease (CKD). However, the phase 3 study, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus: the Occurrence of Renal Events (BEACON), was terminated prematurely because bardoxolone methyl increased the risk for early-onset fluid overload in patients with identifiable risk factors for heart failure (elevated baseline B-type natriuretic peptide levels >200 pg/ml and prior history of hospitalization for heart failure). The Phase 2 Study of Bardoxolone Methyl in Patients with Chronic Kidney Disease and Type 2 Diabetes (TSUBAKI) study aimed to determine if patients without risk factors can mitigate the risk for fluid overload and whether changes in eGFR with bardoxolone methyl reflect true increases in GFR. METHODS: This phase 2, randomized, multicenter, double-blind, placebo-controlled study enrolled patients with type 2 diabetes and stage 3-4 CKD. Patients were randomized 1:1 to bardoxolone methyl (n = 41) or placebo (n = 41) (cohort G3), or 2:1 to bardoxolone methyl (n = 24) or placebo (n = 14) (cohort G4), administered orally once daily for 16 weeks using a dose-titration scheme. The primary efficacy endpoint was change from baseline in GFR measured by inulin clearance at week 16 in the cohort G3. RESULTS: A total of 40 patients were evaluated for the prespecified primary efficacy analysis. Mean change (95% confidence interval [CI]) from baseline in GFR was 5.95 (2.29 to 9.60) and -0.69 (-3.83 to 2.45) ml/min per 1.73 m2 for patients randomized to bardoxolone methyl and placebo, respectively, with a significant intergroup difference of 6.64 ml/min per 1.73 m2 (P = 0.008). Increases in the albumin/creatinine ratio were observed in the bardoxolone methyl group vs the placebo group. The most common adverse events (≥15% in either group) were viral upper respiratory tract infection, increased alanine aminotransferase, increased aspartate aminotransferase, increased γ-glutamyltransferase, and constipation. Peripheral edema was reported by 4 patients receiving bardoxolone methyl and by 1 patient receiving placebo; all events were mild and self-limiting. No patient died or experienced heart failure. The study discontinuation rate was higher in the bardoxolone methyl group (cohort G3, n = 8; cohort G4, n = 7) than the placebo group (cohort G3, n = 1; cohort G4, n = 0). CONCLUSION: Bardoxolone methyl significantly increased measured GFR, and further investigation is ongoing to evaluate whether it provides clinical benefit without major safety concerns in selected patients with CKD.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Nangaku M, Kanda H, Takama H, et al. Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study). Kidney Int Rep. 2020. PMID: 32518870. doi:10.1016/j.ekir.2020.03.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。